CB2 RECEPTOR THERAPY USING THE FDA-APPROVED DRUG RALOXIFENE TO MITIGATE VISUAL DEFICITS AFTER MILD TBI AND/OR OCULAR TRAUMA

University Of Tennessee, Memphis TN

Investigators